Abstract:ABSTRACT Improved broad-spectrum influenza virus vaccines are desperately needed to provide protection against both drifted seasonal and emerging pandemic influenza A viruses (IAVs). Antibody-based protection from influenza A virus-induced morbidity and mortality is traditionally associated with neutralizing antibodies. As such, vaccine efforts have solely focused on the hemagglutinin (HA) as a vaccine target; however, the HA is mutation prone resulting in the need for annual vaccine reformulation. Broad-spectrum vaccines could be achieved through non-neutralizing antibodies that target conserved influenza virus antigens. Here, we describe six human monoclonal antibodies (mAbs) isolated from two H3N2-infected donors that showed robust binding against the conserved internal nucleoprotein (NP) or matrix protein 1 (M1) of IAV strains. Despite the capacity for potent antigen binding, substantial morbidity was observed in mice prophylactically treated with these mAbs and then challenged with A/Netherlands/602/2009 (H1N1) or A/Switzerland/9715293/2013 (H3N2) viruses. While our findings need to be confirmed with a larger number of mAbs and with polyclonal serum, these findings suggest that human NP and M1 antibodies that are elicited following IAV infection/vaccination do not protect from substantial weight loss in the mouse model and imply that protection afforded targeting these antigens following vaccination/infection is most likely the result of cellular-based immunity. IMPORTANCE Currently, many groups are focusing on isolating both neutralizing and non-neutralizing antibodies to the mutation-prone hemagglutinin as a tool to treat or prevent influenza virus infection. Less is known about the level of protection induced by non-neutralizing antibodies that target conserved internal influenza virus proteins. Such non-neutralizing antibodies could provide an alternative pathway to induce broad cross-reactive protection against multiple influenza virus serotypes and subtypes by partially overcoming influenza virus escape mediated by antigenic drift and shift. Accordingly, more information about the level of protection and potential mechanism(s) of action of non-neutralizing antibodies targeting internal influenza virus proteins could be useful for the design of broadly protective and universal influenza virus vaccines.

Broadly protective human antibodies that target the active site of influenza virus neuraminidase

Characterization of non-neutralizing human monoclonal antibodies that target the M1 and NP of influenza A viruses

Protective human monoclonal antibodies target conserved sites of vulnerability on the underside of influenza virus neuraminidase

Conserved sites on the influenza H1 and H3 hemagglutinin recognized by human antibodies

Protective human antibodies against a conserved epitope in pre- and postfusion influenza hemagglutinin

Two Escape Mechanisms of Influenza A Virus to A Broadly Neutralizing Stalk-Binding Antibody

Structural basis of broad protection against influenza virus by a human antibody targeting the neuraminidase active site via a recurring motif in CDR H3

Influenza Neuraminidase Characteristics and Potential as a Vaccine Target

Generation and Characterization of Monoclonal Antibodies Against the Hemagglutinin of H3N2 Influenza A Viruses.

A Broadly Protective Therapeutic Antibody Against Influenza B Virus with Two Mechanisms of Action

Identification and Structural Characterization of a Broadly Neutralizing Antibody Targeting a Novel Conserved Epitope on the Influenza Virus H5N1 Hemagglutinin

Broadly protective bispecific antibodies that simultaneously target influenza virus hemagglutinin and neuraminidase

An in vivo human-plasmablast enrichment technique allows rapid identification of therapeutic influenza A antibodies.

A new class of antibodies that overcomes a steric barrier to cross-group neutralization of influenza viruses

Identification of broad-spectrum neutralizing antibodies against influenza A virus and evaluation of their prophylactic efficacy in mice

Vaccine-Induced Antibodies That Neutralize Group 1 and Group 2 Influenza A Viruses.

Structural Convergence and Water-Mediated Substrate Mimicry Enable Broad Neuraminidase Inhibition by Human Antibodies

Targeting neuraminidase: the next frontier for broadly protective influenza vaccines

The Human Antibody Response to the Influenza Virus Neuraminidase Following Infection or Vaccination

Eliciting a single amino acid change by vaccination generates antibody protection against group 1 and group 2 influenza A viruses

A protective and broadly binding antibody class engages the influenza virus hemagglutinin head at its stem interface